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Expression of functional protease and subviral particles by vaccinia virus
containing equine infectious anaemia virus gag and 5' pol genes
Travis C. McGuire, 1. Katherine I. O'Rourke, z Timothy V. Baszler, 1 Steven R. Leib, 1
Alberta L. Brassfield 1 and William C. Davis I
1 Department o f Veterinary Microbiology and Pathology, College o f Veterinary Medicine,
Washington State University and ~"Animal Disease Research Unit, Agricultural Research Service, U S D A , Pullman,
Washington 99164-7040, U.S.A.

Cells infected with vaccinia viruses expressing the equine
infectious anaemia virus (EIAV) gag gene (VGag) or gag
plus the 5' pol encoding protease (VGag/PR) were
evaluated with monoclonal antibody to a p26 capsid
protein linear epitope (QEISKFLTD). Both recombinant viruses expressed Gag precursor protein (55K)

whereas only VGag/PR expressed a detectable Gag-Pol
fusion protein (82K) with a functional protease, shown
by subviral particles containing processed p26. Horses
inoculated with VGag/PR produced antibodies reactive
with EIAV Gag proteins.

Horses infected with equine infectious anaemia virus
(EIAV) have a life-long infection, characterized in the
first few months by recurrent viraemia with fever,
anaemia, and thrombocytopenia (Cheevers & McGuire,
1988; Clabough et al., 1991). During viremic episodes,
cell-free antigenic variants defined by in vitro neutralizing
antibody assays can be isolated from plasma (Kono et
al., 1973). Mutations occurring in the env gene encoding
gp90 and gp45 cause these antigenic variants (Montelaro
et al., 1984; Payne et al., 1987). Despite variation of
neutralization-sensitive epitopes and other mechanisms
of viral escape, most EIAV-infected horses eventually
become clinically quiescent carriers (Kono et at., 1976).
That lymphocyte responses are involved in EIAV control
is demonstrated by the failure of foals with congenital
severe combined immunodeficiency, which lack B and T
lymphocytes, to terminate viraemia (Perryman et at.,
1988). Also, EIAV carrier horses treated with immunosuppressive drugs have viraemic episodes (Kono et al.,
1976).
EIAV could be controlled by several potentially
protective immune responses including neutralizing
antibody, cytotoxic T lymphocytes or antibody-dependent mechanisms of cytotoxicity. Studies of protective
immune responses to lentiviruses have emphasized
envelope glycoproteins. However, some have demonstrated cytotoxic T lymphocyte responses to human
immunodeficiency virus type 1 (HIV-1) and simian
immunodeficiency virus Gag proteins (Riviere et al.,
1989; Johnson et aL, 1991 ; Littaua et aL, 1991 ; Yasuhiro
et al., 1993). Immune responses to epitopes on the gagencoded proteins may be important because the rate of

divergence in gag is low compared to env in HIV-1 (Li et
al., 1988) and in EIAV (Perry et al., 1992). The EIAV gag
gene contains 1458 nucleotides (nt) encoding a 55K Gag
precursor protein (Montelaro et al., 1982; Stephens et
at., 1986; Hussain et at., 1988) which is proteolytically
cleaved into proteins including p15 matrix, p26 capsid,
p 11 nucleocapsid, and p9 of unknown function (Henderson et al., 1987). A 10K protease encoded by the EIAV
pol gene and expressed in Escherichia coli cleaves the Gag
precursor to yield p26 (Rushlow et aL, 1992). To evaluate
Gag protein synthesis and processing in eukaryotic cells
and to aid the dissection of immune responses to Gag
proteins, recombinant vaccinia viruses expressing EIAV
Gag proteins and protease were evaluated.
Viral RNA for cDNA cloning was isolated (O'Rourke
et al., 1991) from EIAV-WSU5, a pathogenic cell cultureadapted strain isolated after three sequential passages of
prototype EIAV in horses and then three limiting
dilutions in cell cultures (O'Rourke et al., 1988). Firststrand synthesis was primed with an oligonucleotide
corresponding to nt 2582 to 2599 of prototype EIAV
provirus (Kawakami et al., 1987) followed by secondstrand synthesis (Gubler & Hoffman, 1983). Plasmids
made by annealing dG-tailed cDNA to dC-tailed pUC19
were used to transform DH5~ E. coli. Isolated plasmid
pEIA5G contained a 2.2 kb EIAV cDNA insert and
both strands were sequenced (GenBank accession no.
L06609) using the dideoxynucleotide chain termination
method. The sequence corresponded to nt 340 to 2578 of
prototype provirus (Fig. 1) with the 1458 nt EIAVWSU5 gag sequence being identical to that of prototype
gag (Kawakami et al., 1987). However, there were three
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Fig. 1. Diagram of EIAV genes used to construct recombinant vaccinia
viruses. EIAVproviral gag and 5' pol (from Kawakami et al,, 1987; the
completepol extends to nt 5120)is at the top followedby a cDNA clone
of the EIAV-WSU5gag and 5' pol in pEIA5G and the fragments of
pEIA5G used to construct recombinant vaccima viruses, VGag/PR
and VGag. RT, Reverse transcriptase.
nucleotide differences in 5' poh an A at position 2058
changing arginine to lysine in the predicted protease
sequence, a synonymous C at 2341, and an A at 2441
changing glycine to serine in the predicted reverse
transcriptase. By comparison, the WSU5 env gene has
13 nt and six amino acid differences from the 2580 nt of
prototype env (McGuire et al., 1990). Like prototype
EIAV, expression of Pol proteins from the WSU5
gag-pol transcript requires a ribosomal frameshift
(Stephens et al., 1986). The frameshift may occur at a
heptanucleotide site associated with ribosomal frameshifting in other retroviruses (Hatfield et al., 1992) and
predicted for EIAV (Montelaro et al., 1993); this is
A A A A A A C located 40 nt into the gag-pol gene overlap.
To identify EIAV Gag proteins expressed by recombinant viruses, a monoclonal antibody (MAb) binding p26
was defined. The hybridoma producing M A b EIA6A1,
an IgG1 isotype, was derived by fusing spleen cells from
a B A L B / c mouse immunized with EIAV prototype
strain with X 6 3 . A G 8 . 6 5 3 myeloma cells and cloned
twice by limiting dilution (Davis et al., 1983). This M A b
reacted in immunoblots with 55K and 26K EIAV
proteins and two other minor proteins (Fig. 2 a, lane 7).
The specificity of M A b EIA6A1 for p26 was defined by
mapping the epitope using overlapping hexamers of the
p26 amino acid sequence synthesized on plastic pegs
(Geysen et al., 1984; Cambridge Research Biochemicals).
Significant M A b EIA6A1 binding occurred with hexamers encompassing the amino acid sequence Q E I S K F L T D (Table 1) corresponding to amino acids 179 to 187
of processed p26 (Stephens et al., 1986). This epitope is
also in the 83 amino acid C terminus of p26 previously
identified as a highly immunogenic domain (Chong et al.,
1991).
To demonstrate that the EIAV 55K Gag precursor
was processed by the pol-encoded protease rather than
cellular proteases and to have vectors which correctly
processed Gag proteins, two recombinant vaccinia
viruses were made. VGag contained only the gag gene
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Fig. 2. Immunoblot of recombinant vaccmia virus-expressed gag
proteins. (a) Lysates from HeLa cells (lanes 1 to 3) and equine kidney
cells (lanes 4 to 6) infected with VGag/PR. VGag or VSCll,
respectively, and 2 gg EIAV (lane 7) were reacted with MAb EIA6A1.
(b) Lysates of TK- 143B cells (lanes 1 to 3) infected with VGag/PR,
VGag or VSC11, were reacted with serum from horse A-1924taken 60
days after EIAV infection. Neither an isotype control MAb nor
preinfectlon serum from A-1924 reacted with duplicate immunoblots
(data not shown). M~. standards are shown on the left.
Table 1. Reactivity of M A b EIA6A1 with overlapping

hexamers derived from the EIA V p26 amino acid
sequence
Peptide no.

Amino acid
sequence

ELISA A40s

180
181
182
183
184
185
186
187
188
189

GHPQEI
HPQEIS
PQEISK
QEISKF
EISKFL
ISKFLT
SKFLTD
KFLTDT
FLTDTL
LTDTLT

0"017
0"016
0"012
0"202*
0"306*
0"298*
0"122*
0"027
0"016
0"015

* The A~0s values for peptides 1 to 182 and 187 to 250 did not exceed
0.032.
(Fig. 1) and was made with an insertion plasmid derived
by ligating the SmaI-XbaI fragment of EIAV c D N A
from p E I A 5 G containing nt 394 to 1937 (Kawakami et
aL, 1987) to Sinai-digested p S C l l (Chakrabarti et al.,
1985). Prior to ligation, the 5' overhang resulting from
the XbaI digest was filled using the Klenow fragment of
D N A polymerase I. The Sinai cloning site in pSC11 is
downstream of the P7"5 vaccinia virus promoter and the
translation initiation codon for the cloned EIAV gag
gene was the first A T G in the SmaI-XbI fragment which
was located 72 nt downstream from the Sinai site.
V G a g / P R contained gag and 5' pol genes encoding
protease (Fig. 1). V G a g / P R was made with an insertion
plasmid derived by ligating the Sinai fragment from
p E I A 5 G containing nt 394 to 2526 to SmaI-digested
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pSC11. It was predicted to make the Gag precursor and
also to have a ribosomal frameshift to produce a
detectable Gag-Pol fusion protein (Stephens et al.,
1986). A control vaccinia virus, VSCll, was made with
pSCll without an EIAV cDNA insert. The insertion
plasmids were characterized by restriction endonuclease
digestion and nucleotide sequencing of all ligation sites.
The insertion plasmid, pSCll, also contains the flgalactosidase gene driven by the P l l vaccinia virus
promoter (Chakrabarti et al., 1985) and following
homologous recombination with vaccinia virus WR
strain in infected cells, 5-bromo-4-chloro-3-indolyl-Dgalactopyranoside was added to the agarose overlay
allowing visual detection of recombinant virus as a blue
plaque. Selected recombinants were plaque-purified three
times in BSC-1 cells.
The Gag proteins made by recombinant vaccinia
viruses were identified by immunoblotting infected cell
lysates. HeLa and neonatal equine kidney cells, in wells
of a 24-well plate, were infected with 10p.f.u./cell
for 24 h. Infected cells were lysed with 0"5 % NP40 in
50 mM-Tris-HC1 pH 8, containing 5 mM-EDTA, 5 mMiodoacetamide, 0.1 mM-TLCK and 1 mM-PMSF for
30rain on ice and centrifuged at 12000g for 5min.
Proteins in the supernatant were separated by SDSPAGE, transferred to nitrocellulose and probed with
either MAb or serum from an Arabian horse 60 days
after infection with EIAV-WSU5 (Perryman et al., 1988).
Bound primary antibodies were detected with either antimouse or anti-horse immunoglobulin antibodies conjugated to horseradish peroxidase and substrate for
chemiluminescence (McGuire et al., 1992). Cell cultures
infected with VGag and VGag/PR produced a 55K
protein, identified as the Gag precursor by its size and
reactivity in immunoblots with MAb EIA6AI (Fig. 2a,
lanes 1, 2, 4 and 5). In addition, cell cultures infected with
VGag/PR, but not VGag, expressed an 82K protein
reactive with MAb EIA6A1 (Fig. 2a, lanes 1 and 4). This
protein corresponded to the predicted truncated Gag-Pol
fusion protein beginning with an initiation codon at nt
465, having a ribosomal frameshift in the overlap region,
and continuing through nt 2526 to a termination codon
18 nt downstream in pSC11. IfVGag encoded a Gag-Pol
fusion protein involving the 244 nt overlap region, it was
predicted to be approximately 55K and indistinguishable
from the 55K Gag precursor protein by immunoblots
using the antibodies described. Reactivity of MAb
EIA6A1 with isolated EIAV resulted in a strong p26
band and a weak reaction with the 55K precursor protein
(Fig. 2a, lane 7), presumably because of the low amount
of this latter protein in EIAV. Serum antibodies from an
EIA¥-infected horse bound both the 55K and 82K
proteins in cell lysates whereas serum taken before
infection did not bind these proteins (Fig. 2b). p26 was
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not demonstrated in any of these immunoblots; however,
MAb EIA6A1 bound 41K, 44K, 47K and 50K proteins
in lysates from VGag- and VGag/PR-infected HeLa cells
(Fig. 2a, lanes 1 and 2) and horse serum antibodies to
EIAV bound similar proteins in VGag- and VGag/PRinfected thymidine kinase-negative ( T K ) 143B cells
(Fig. 2 b). Since these partially processed Gag proteins
were present in lysates of cells infected with either
construct, they did not result from the protease encoded
by EIAV pol. It is likely these fragments were generated
by cellular or vaccinia virus proteases. Cells infected with
a recombinant vaccinia virus expressing HIV-1 gag-pol
genes processed the 55K Gag precursor to p24 with three
intermediates including p39, p41a and p41b (Gowda et
al., 1989a). Whether these HIV-1 Gag protein intermediates are similar to EIAV Gag proteins described
above and attributed to cellular or vaccinia virus
proteases is unknown.
Failure to detect p26 in recombinant virus-infected cell
lysates prompted an examination of these cells for
subviral particles which might contain processed p26
(Gowda et aI., 1989b; Karacostas et al., 1989). For
transmission electron microscopy, equine kidney cells in
25 cm 2 tissue culture flasks were inoculated with 10

Fig. 3. Electronmmrographsof retrovirus-likeparticlesin thin sections
of VGag/PR-infectedequinekidneycells. Bothvacciniavirusparticles
(V) and incompleteEIAV particles (arrowheads) are present in the
cytoplasm. Bar represents 200nm. Inset: retrovirus-like particles
budding from the cell membrane;bar represents 100 nm.
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Fig. 4. I m m u n o b l o t of s u b v l r a l particles i s o l a t e d f r o m r e c o m b i n a n t
v a c c i n i a virus-infected cell cultures. L a n e s 1 to 3 c o n t a i n e d particles
i s o l a t e d f r o m culture s u p e r n a t a n t s from equine k i d n e y cells infected
w i t h VSC11, V G a g / P R a n d V G a g , respectively. All lanes were reacted
w i t h M A b E I A 6 A 1 . A n isotype c o n t r o l M A b did n o t react w i t h a
d u p l i c a t e i m m u n o b l o t M r s t a n d a r d s are s h o w n on the left.

p.f.u./cell of either VGag/PR, VGag or VSC11. After
24 h, cells were fixed with 4 % paraformaldehyde/2 %
glutaraldehyde in 0.1 M-cacodylate buffer at pH 7.4.
Fixed cells were removed by scraping, pelleted in agarose,
post-fixed in 1% osmium tetroxide, and embedded in
Epon. Ten ultrathin sections from each group were
stained with uranyl acetate and lead citrate and examined. Cells infected with VGag/PR had both
retrovirus-like particles and vaccinia virus particles that
were distinguishable by size and morphology (Fig. 3).
The retrovirus-like particles in VGag/PR-infected cells
were not complete and were found free in the cytoplasm
and budding from the cell membrane. Budding particles
had a double-layered membrane with an electron-lucent
centre and ranged from 90 to 110 nm in diameter (Fig.
3). Their morphology was similar to the particles
described in cells infected with recombinant vaccinia
virus or baculoviruses expressing the HIV-1 gag gene
(Karacostas et al., 1989; Gheysen et al., 1989). Cells
infected with VGag had subviral and vaccinia virus
particles similar to those described for VGag/PR
whereas cells infected with VSC 11 had vaccinia virus, but
no subviral retrovirus-like particles.
To examine subviral particles for p26, they were
isolated and immunoblotted as described for cell lysates.
Particles were removed from culture medium by centrifugation at 120000 g for 3 h, resuspended in PBS, layered

Fig. 5. I m m u n o b l o t o f E I A V p r o t e i n s w i t h a n t i b o d i e s f r o m horses
i m m u n i z e d w i t h V G a g / P R . E v e r y lane c o n t a i n e d 0.5 Ixg E I A V a n d all
a n t i b o d i e s were diluted 500-fold. L a n e s 1 a n d 2 were reacted w i t h sera
f r o m V G a g / P R - i m m u n i z e d horses H-472 a n d H481, respectively.
Lanes 3 a n d 6 were reacted w i t h sera f r o m horse A-1924 after a n d
before E1AV infection, respectively. L a n e s 4 a n d 5 were reacted w i t h
sera f r o m V S C 1 1 - i m m u n i z e d horses H-479 a n d H-482, respectively. M r
s t a n d a r d s are s h o w n o n the left.

onto a 15 % sucrose cushion, and centrifuged at 120 000 g
for 90 rain (Haffar et al., 1991). Particles from VGag/PRinfected cells, and not from VGag-infected cells, contained processed p26 which reacted with MAb EIA6A1
(Fig. 4) demonstrating that processing of the p26
depended on the viral protease. Presence of capsid
protein in EIAV subviral particles here and in HIV-1
particles (Gowda et al., 1989b; Karacostas et al., 1989)
may be accounted for by protease cleavage of Gag
precursor protein after particle assembly.
To determine whether VGag/PR would induce an
immune response to EIAV Gag proteins, two horses
(Shetland ponies H-472 and H-481) were immunized
intradermally in each of four locations with l0 s p.f.u, of
VGag/PR and were boosted with the same dose at 4 and
12 months later. Two control horses (Shetland ponies H479 and H-482) were similarly immunized with VSC11.
Sera collected 2 weeks after the last boost were analysed
for antibodies to EIAV by immunoblotting. The VGag/
PR-immunized horses produced antibodies to EIAV
Gag proteins, particularly p26 (Fig. 5, lanes 1 and 2).
Longer development of these immunoblots demonstrated antibodies to p15 and p l l proteins (data not
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shown). The VSC11-immunized horses did not produce
antibodies to EIAV Gag proteins (Fig. 5, lanes 4 and 5).
Several conclusions can be drawn from the structural
analysis of the EIAV gag and 5' pol genes and the
functional and immunological analysis of Gag proteins
produced by recombinant vaccinia viruses. (i) Following
sequential in vivo passages, the gag precursor sequence
was more highly conserved in the clone we sequenced
than either the 5' pol or env sequence. (ii) Cells infected
with VGag/PR expressing the gag and 5' po! genes
produced a predicted 82K Gag-Pol fusion protein
demonstrating that the ribosomal frameshift necessary
for translation of the protease gene from the gag-pol
transcript occurred. (iii) The protease in the 82K
Gag-Pol fusion protein was functional in equine cells
(the only cell line examined for subviral particles) since
the 55K Gag precursor was processed to p26 in subviral
particles. This also indicated that the viral protease was
unaffected by a naturally occurring mutation changing
arginine to lysine. (iv) Expressed Gag proteins were
bound by antibodies in serum from an EIAV-infected
horse, and horses immunized with VGag/PR produced
antibodies which bound EIAV Gag proteins. Based on
these results, recombinant vaccinia virus VGag/PR
produced functional Gag proteins and can be used
further to examine T lymphocyte responses in EIAV
carriers.
The authors appreciate the research assistance of Theresa Harkins,
Eldon Libstaff, Sue Pritchard, Kathleen Reeve, Ruth Brown and
Emma Karel. This research was supported in part by the National
Institutes of Health grant AI24291, the Morris Animal Foundation,
and the Washington Technology Center.
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